| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Mulberroside A targets multiple pathways involved in inflammation and oxidative stress. It inhibits the production of pro-inflammatory cytokines and reduces oxidative stress through its antioxidant properties. The compound also activates nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant response genes. Its hepatoprotective effects are mediated through reduction of oxidative damage and inflammation in the liver.
|
|---|---|
| ln Vitro |
In vitro, mulberroside A exhibits anti-inflammatory and antioxidant activities. It inhibits the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in stimulated immune cells. The compound scavenges free radicals and reduces oxidative stress in various cell types. Its hepatoprotective effects are demonstrated by protecting hepatocytes from oxidative stress-induced damage.
|
| ln Vivo |
Mulberroside A (10, 20 and 40 mg/kg) reduces serum uric acid levels and increases uric acid excretion and fractional uric acid excretion in hyperuricemic mice [4].
In vivo, mulberroside A has been studied in animal models of inflammation and liver disease. It reduces inflammatory markers and oxidative stress in models of acute and chronic inflammation. The compound shows hepatoprotective effects in models of liver injury, reducing liver enzyme levels and improving histological outcomes. Its antioxidant properties contribute to its protective effects. |
| Enzyme Assay |
In vitro enzyme assays for mulberroside A measure its antioxidant activity using DPPH radical scavenging, ABTS radical scavenging, or FRAP assays. Anti-inflammatory activity is assessed by measuring cytokine production in stimulated immune cells. Nrf2 activation is measured using reporter gene assays or by measuring the expression of Nrf2 target genes. The compound's effects on specific enzymes involved in inflammation and oxidative stress are also evaluated.
|
| Cell Assay |
In vitro cell-based assays for mulberroside A use immune cells (macrophages, microglia) or hepatocytes. Cells are treated with serial dilutions of the compound, and inflammatory cytokine production is measured by ELISA or qPCR. Oxidative stress is assessed by measuring ROS levels, lipid peroxidation, and antioxidant enzyme activities. Hepatoprotective effects are assessed by measuring cell viability and liver enzyme release in hepatocytes exposed to toxicants.
|
| Animal Protocol |
Animal/Disease Models: Male Kunming mouse (20±2 g) [4]
Doses: 5, 10, 20, 40 mg/kg; dose volume 10 mL/kg Body weight Route of Administration: 9:00 am Oral start Experimental Results: 10, 20 and 40 mg/kg Dramatically increased urate excretion within 24 hrs (hrs (hours)), resulting in a significant increase in fractional uric acid excretion (FEUA), and the highest dose completely reversed the FEUA changes in hyperuricemic mice to normal. In vivo animal models for mulberroside A include mouse models of inflammation (e.g., LPS-induced inflammation) and liver injury (e.g., CCl4-induced liver injury). The compound is administered orally or intraperitoneally, and its effects on inflammatory markers, oxidative stress, and liver pathology are evaluated. Pharmacodynamic studies measure Nrf2 activation and antioxidant gene expression in tissues. |
| ADME/Pharmacokinetics |
Mulberroside A has a molecular formula of C26H32O9 and a molecular weight of 488.53. It is a bioactive stilbenoid glycoside isolated from the root bark of Morus alba. The compound is soluble in DMSO and other organic solvents. It is stored as a powder at -20°C. Pharmacokinetic parameters including absorption, distribution, metabolism, and excretion are documented in research publications.
|
| Toxicity/Toxicokinetics |
The toxicity profile of mulberroside A is favorable, as it is a natural compound with a long history of use in traditional medicine. It is generally well-tolerated at therapeutic doses. High doses may cause gastrointestinal discomfort. The compound is not known to be genotoxic or carcinogenic at relevant exposure levels. It is used for research purposes only.
|
| References |
|
| Additional Infomation |
cis-molarin A is a glycoside and stilbene compound. It has been reported to exist in mulberry trees, Veratrum nigrum, and other organisms with relevant data.
Mulberroside A is a bioactive stilbenoid glycoside isolated from the root bark of Morus alba (white mulberry). It exhibits various pharmacological activities including anti-inflammatory, antioxidant, and hepatoprotective effects. The compound activates Nrf2, a key regulator of antioxidant response genes, and inhibits pro-inflammatory cytokine production. Mulberroside A is used for research purposes in natural product pharmacology. |
| Molecular Formula |
C26H32O14
|
|---|---|
| Molecular Weight |
568.5239
|
| Exact Mass |
568.179
|
| CAS # |
102841-42-9
|
| Related CAS # |
cis-Mulberroside A;166734-06-1
|
| PubChem CID |
6443484
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
954.7±65.0 °C at 760 mmHg
|
| Flash Point |
531.2±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.742
|
| LogP |
-1.16
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
816
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=C(C=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)/C=C/C3=CC(=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
HPSWAEGGWLOOKT-VUNDNAJOSA-N
|
| InChi Code |
InChI=1S/C26H32O14/c27-9-17-19(31)21(33)23(35)25(39-17)37-14-4-3-12(16(30)8-14)2-1-11-5-13(29)7-15(6-11)38-26-24(36)22(34)20(32)18(10-28)40-26/h1-8,17-36H,9-10H2/b2-1+/t17-,18-,19-,20-,21+,22+,23-,24-,25-,26-/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[3-hydroxy-4-[(E)-2-[3-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~175.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (17.59 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7590 mL | 8.7948 mL | 17.5895 mL | |
| 5 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL | |
| 10 mM | 0.1759 mL | 0.8795 mL | 1.7590 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
